| 000 | 01694 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517123219.0 | ||
| 264 | 0 | _c20170911 | |
| 008 | 201709s 0 0 eng d | ||
| 022 | _a1502-7708 | ||
| 024 | 7 |
_a10.1080/00365521.2016.1250942 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMolander, Pauliina | |
| 245 | 0 | 0 |
_aLong-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents. _h[electronic resource] |
| 260 |
_bScandinavian journal of gastroenterology _cMar 2017 |
||
| 300 |
_a284-290 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study | ||
| 650 | 0 | 4 |
_aAdalimumab _xtherapeutic use |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFinland |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInflammatory Bowel Diseases _xclassification |
| 650 | 0 | 4 |
_aInfliximab _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aFärkkilä, Martti | |
| 700 | 1 | _aKemppainen, Helena | |
| 700 | 1 | _aBlomster, Timo | |
| 700 | 1 | _aJussila, Airi | |
| 700 | 1 | _aMustonen, Harri | |
| 700 | 1 | _aSipponen, Taina | |
| 773 | 0 |
_tScandinavian journal of gastroenterology _gvol. 52 _gno. 3 _gp. 284-290 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/00365521.2016.1250942 _zAvailable from publisher's website |
| 999 |
_c26571359 _d26571359 |
||